Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Poliovirus Vaccination Status Among Adult Europeans in the Vaccelerate Volunteer Registry
30 Pages Posted: 25 Jul 2023
More...Abstract
Background: In 2022, cases of poliomyelitis related to circulating vaccine derived polioviruses (cVDPV) occurred in unvaccinated persons in former “polio-free” regions. Poliovirus (PV) vaccination coverage in non-endemic countries needs to be elucidated.
Methods: To assess the PV vaccination coverage in Europe, the VACCELERATE Volunteer Registry was used. Between Oct-28, 2022 and Nov-23, 2022, 5.989 of 31.333 (19%) volunteers completed an electronic case report form on their prior PV vaccine doses including number, vaccine types/-valencies and the time of administration. A uni-/multivariable regression analysis was performed to assess significant associations in patient characteristics and immunization status.
Findings: Most participants originated from Germany (97%), followed by Ireland (2%) and Austria (1%). Among German volunteers (n=5.449), complete vaccination status was found in 1.981 (36%) volunteers. Uncertain vaccination status, due to unknown previous PV vaccination (n=313, 6%), number of doses (n=497, 9%), vaccine types /-valencies (n=1.233, 23%) or incoherent immunization schedule (n=149, 3%) was found in 40% (n=2.192). Of 1.276 (23%) volunteers who reported incomplete immunization, 62 (1%) reported never having received a PV vaccine. Regarding lifetime prevalence for PV vaccination, 5.074 (93%) volunteers reported having been vaccinated at least once. Concerning time of administration, 2.087 (38%) participants indicated that they received PV vaccination within the last ten years. No significant regional differences were observed in terms of vaccination status. Women, younger age, as well as maintenance of first vaccination record were characteristics statistically significant associated with complete immunization (P<.001).
Interpretation: PV vaccination status is difficult to assess due to the lack of specific details on previously administered doses, in particular vaccine types and/or valencies, indicating the need for improved vaccination recording to enable long-term access to detailed vaccination data and understanding by the general population.
Funding: VACCELERATE has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 101037867.
Declaration of Interest: JSG has received speaker honoraria from Gilead and Pfizer. HJS has received consultancy or speaker honoraria from Pfizer, CSL Seqirus, Sanofi, Cologne University, Global Health Press, Minervax, VacciZONE and GOPA/KfW. JS has received research grants by the Ministry of Education and Research (BMBF) and Basilea Pharmaceuticals Inc.; has received speaker honoraria by Pfizer Inc., Gilead and AbbVie; has been a consultant to Gilead, Produkt&Markt GmbH, Alvea Vax. and Micron Research, and has received travel grants by German Society for Infectious Diseases (DGI e.V.) and Meta-Alexander Foundation. PWGM has received honoraria and/or travel grants from Astrazeneza, Gilead Sciences, ViiV, Janssen and Pfizer. AC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, Pfizer, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Noscendo, Pfizer, Shionogi; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi, The Prime Meridian Group; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Stocks from CoRe Consulting, and EasyRadiology. JAN, LC, MZ and ZDP have nothing to declare.
Ethical Approval: The VACCELERATE Volunteer Registry, which was approved by the Ethics Commission of Cologne University’s Faculty of Medicine (Germany) (identifier 20–1536) was used.
Keywords: Polio, outbreaks, recurrence, non-endemic, vaccine preventable, immunization, population, vaccination coverage, public health, surveillance, infection control
Suggested Citation: Suggested Citation